Corporate Profile for Structural Bioinformatics, dated Jan. 24, 1997.--(BUSINESS WIRE)--The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and information services See Information Systems. . These include Dow Jones News/Retrieval, Bloomberg Financial Markets, Reuter Company Newsyear, Reuter Business Briefing, DataTimes, Nexis, Dialog, NewsNet, America OnLine, CompuServe, Delphi, Individual's HeadsUp and First!, Desktop Data's NewsEdge, UMI UMI University Microfilms International UMI United States Minor Outlying Islands (ISO Country code) UMI University of Miami UMI Universal Management Infrastructure (IBM) Data Courier, NewsBank, Information Access Company, Prodigy, Comtex, and many others. -0-
Published Date: Jan. 24, 1997
Company Name: Structural Bioinformatics Inc.
Address: 10929 Technology Place
San Diego, Calif. 92127
Main Telephone
Number: 619/675-2400
Facsimilie: 619/451-3828
Chief Executive
Officer: Edward T. Maggio, Ph.D.
Trading Symbol: Private
Industry: Bioinformatics
Company description: SBI SBI Special Background Investigation SBI Subsidiary Body for Implementation SBI State Bank of India SBI Secure Border Initiative SBI Small Business Institute SBI Stockholm Brain Institute SBI Serious Bacterial Infection SBI Society of Breast Imaging , founded in 1996 in San Diego, Calif., has developed the first structural bioinformatics operating system, making possible the immediate and practical use of genomic (gene sequence) data in a broad range of structure-based drug discovery and design processes. SBI combines recent proprietary breakthroughs in 3-D protein structure modeling and protein structure-based drug design algorithms to facilitate the design and identification of small molecule lead compounds based on novel gene sequences. In effect, SBI bridges the gap between novel gene sequence data generated by genomics researchers and the kind of 3-D dynamic structural information actually required by computational and medicinal chemists to design, synthesize or efficiently screen for new drugs. SBI founders generated successful leads from the 3-D structures of a number of proteins including endothelin and TNF TNF abbr. tumor necrosis factor TNF, n an abbreviation for tumor necrosis f . In fact, IPI-1251 (now TBC-11251), an orally active picomolar endothelin receptor antagonist A endothelin receptor antagonist (ERA) is a drug which blocks endothelin receptors. Two main kinds of ERAs exist:
FGF Future Generation Foundation (Egypt) FGF Feel-Good Factor FGF Federación Gallega de Fútbol (Spain) FGF Fédération Guinéenne de Football (Guinea) receptor antagonists for a major multinational pharmaceutical company. More than a dozen chemically distinct families of cytokine Cytokine Any of a group of soluble proteins that are released by a cell to send messages which are delivered to the same cell (autocrine), an adjacent cell (paracrine), or a distant cell (endocrine). , growth factor, bioactive peptide and monoclonal antibody-derived lead compounds have already been generated using protein structural information derived from SBI's ab initio [Latin, From the beginning; from the first act; from the inception.] An agreement is said to be "void ab initio" if it has at no time had any legal validity. algorithms. The company will build corporate partnerships with pharmaceutical companies, gene discovery companies and combinatorial chemistry companies. The objectives of these partnerships will range from broad technology collaborations to assistance with specific targets or target groups as a means of more fully defining the utility of the technology and resulting SBdBase and to generate an early source of revenues to find expansion of the underlying technology assets. CONTACT: Structural Bioinformatics inc., San Diego |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion